Biogen
Search results
As the leader in RNA-targeted therapeutics for more than three decades, Ionis has focused every moment on advancing drug discovery, development, and providing hope for patients.
- About
Ionis: A force for life. We are guided by world-class...
- Investors & Media
Ionis currently has five marketed medicines and a leading...
- Press Releases
Ionis poised for continued momentum in 2024 with product...
- About
Ionis: A force for life. We are guided by world-class scientists and business leaders whose drive and passion to innovate is matched only by their commitment to deliver first-in-class and best-in-class medicines to the patients who need them. View 2023 Corporate Responsibility Report ».
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics.
Jun 25, 2024 · Ionis is planning additional regulatory filings for the treatment of FCS in the European Union this year. In addition to FCS, Ionis is evaluating olezarsen for the treatment of severe hypertriglyceridemia (sHTG) in three Phase 3 clinical trials – CORE, CORE2 and ESSENCE, all three of which completed enrollment in the first half of 2024.
Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing.
Find the latest Ionis Pharmaceuticals, Inc. (IONS) stock quote, history, news and other vital information to help you with your stock trading and investing.
People also ask
Who is Ionis Pharmaceuticals?
What drugs did Ionis bring to market?
How much does Ionis pay for mipomersen?
Who owns Isis Pharmaceuticals?
Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases
